Investigational drug · Phase 2
ATH-063
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ATH-063"
First trial start
2026
Apr 30, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ATH-063", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ulcerative Colitis
- Inflammatory Bowel Diseases
- Autoimmune Diseases
Approved drugs for the same conditions: Ulcerative colitis · Immunology and inflammation · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ATH-063" as an intervention, largest first.
- Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)Pivotal-lookingRecruiting
Athos Therapeutics IncIndustry
NCT07513181 · 120 participants (planned) · Start Apr 30, 2026 · Primary completion Dec 14, 2028
Drug: ATH-063 · For: Ulcerative Colitis; Inflammatory Bowel Diseases; Autoimmune Diseases
Sites: Miami, Florida; Tampa, Florida; Roswell, Georgia · 4 sites in all
Athos Therapeutics IncIndustry
NCT05807971 · 76 participants · Start Apr 6, 2023 · Primary completion Feb 8, 2024
Drug: ATH-063; Placebo · For: Inflammatory Bowel Diseases; Crohn Disease; Ulcerative Colitis and 1 more
Sites: Adelaide, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Ulcerative Colitis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- DuvakitugSAR447189, TEV-48574 APhase 36 trials
Sanofi · Ulcerative Colitis, Crohn's Disease, Hidradenitis
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- ABX464ObefazimodPhase 35 trials
Abivax S.A. · Ulcerative Colitis, Moderately to Severely Active Crohn Disease
- brivekimigSAR442970Phase 25 trials
Sanofi · Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Type 1 Diabetes Mellitus
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.